-
1
-
-
0033552883
-
Atherosclerosis--an inflammatory disease
-
Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340(2): 115-126.
-
(1999)
N Engl J Med
, vol.340
, Issue.2
, pp. 115-126
-
-
Ross, R.1
-
2
-
-
0032572086
-
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
-
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615-1622.
-
(1998)
JAMA
, vol.279
, Issue.20
, pp. 1615-1622
-
-
Downs, J.R.1
Clearfield, M.2
Weis, S.3
-
3
-
-
0028883828
-
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
-
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301-1307.
-
(1995)
N Engl J Med
, vol.333
, Issue.20
, pp. 1301-1307
-
-
Shepherd, J.1
Cobbe, S.M.2
Ford, I.3
-
4
-
-
0032487931
-
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
-
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
-
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19): 1349-1357.
-
(1998)
N Engl J Med
, vol.339
, Issue.19
, pp. 1349-1357
-
-
-
5
-
-
0342981862
-
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
-
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14): 1001-1009.
-
(1996)
N Engl J Med
, vol.335
, Issue.14
, pp. 1001-1009
-
-
Sacks, F.M.1
Pfeffer, M.A.2
Moye, L.A.3
-
6
-
-
5444260617
-
Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients
-
Ascer E, Bertolami MC, Venturinelli ML, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004; 177(1): 161-166.
-
(2004)
Atherosclerosis
, vol.177
, Issue.1
, pp. 161-166
-
-
Ascer, E.1
Bertolami, M.C.2
Venturinelli, M.L.3
-
7
-
-
34447264741
-
Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome
-
Bulcao C, Ribeiro-Filho FF, Sanudo A, Roberta Ferreira SG. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 2007; 7(3): 219-224.
-
(2007)
Am J Cardiovasc Drugs
, vol.7
, Issue.3
, pp. 219-224
-
-
Bulcao, C.1
Ribeiro-Filho, F.F.2
Sanudo, A.3
Roberta Ferreira, S.G.4
-
8
-
-
0037212882
-
Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus
-
van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166(1): 129-135.
-
(2003)
Atherosclerosis
, vol.166
, Issue.1
, pp. 129-135
-
-
van de Ree, M.A.1
Huisman, M.V.2
Princen, H.M.3
Meinders, A.E.4
Kluft, C.5
-
9
-
-
79961031512
-
Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling
-
Antoniades C, Bakogiannis C, Leeson P, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011; 124(3): 335-345.
-
(2011)
Circulation
, vol.124
, Issue.3
, pp. 335-345
-
-
Antoniades, C.1
Bakogiannis, C.2
Leeson, P.3
-
10
-
-
77957221105
-
Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity
-
Antoniades C, Bakogiannis C, Tousoulis D, et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010; 122(11 Suppl): S66-S73.
-
(2010)
Circulation
, vol.122
, Issue.11 SUPPL.
-
-
Antoniades, C.1
Bakogiannis, C.2
Tousoulis, D.3
-
11
-
-
0344563476
-
HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease
-
Jarvisalo MJ, Toikka JO, Vasankari T, et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999; 147(2): 237-242.
-
(1999)
Atherosclerosis
, vol.147
, Issue.2
, pp. 237-242
-
-
Jarvisalo, M.J.1
Toikka, J.O.2
Vasankari, T.3
-
12
-
-
0033614802
-
Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
-
Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99(25): 3227-3233.
-
(1999)
Circulation
, vol.99
, Issue.25
, pp. 3227-3233
-
-
Dupuis, J.1
Tardif, J.C.2
Cernacek, P.3
Theroux, P.4
-
13
-
-
0037465733
-
Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans
-
Cipollone F, Fazia M, Iezzi A, et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003; 107(11): 1479-1485.
-
(2003)
Circulation
, vol.107
, Issue.11
, pp. 1479-1485
-
-
Cipollone, F.1
Fazia, M.2
Iezzi, A.3
-
14
-
-
0035804846
-
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
-
Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285(13): 1711-1718.
-
(2001)
JAMA
, vol.285
, Issue.13
, pp. 1711-1718
-
-
Schwartz, G.G.1
Olsson, A.G.2
Ezekowitz, M.D.3
-
15
-
-
53049095795
-
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial
-
Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9645): 1231-1239.
-
(2008)
Lancet
, vol.372
, Issue.9645
, pp. 1231-1239
-
-
Tavazzi, L.1
Maggioni, A.P.2
Marchioli, R.3
-
16
-
-
2642536741
-
Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents
-
Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109(21 Suppl 1): II18-II26.
-
(2004)
Circulation
, vol.109
, Issue.21 SUPPL. 1
-
-
Schonbeck, U.1
Libby, P.2
-
17
-
-
77953285918
-
Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering
-
Gounari P, Tousoulis D, Antoniades C, et al. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int J Cardiol 2010; 142(1): 87-91.
-
(2010)
Int J Cardiol
, vol.142
, Issue.1
, pp. 87-91
-
-
Gounari, P.1
Tousoulis, D.2
Antoniades, C.3
-
18
-
-
20844463066
-
Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans
-
Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111(18): 2356-2363.
-
(2005)
Circulation
, vol.111
, Issue.18
, pp. 2356-2363
-
-
Landmesser, U.1
Bahlmann, F.2
Mueller, M.3
-
19
-
-
6944240055
-
Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: National registry of myocardial infarction
-
Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med 2004; 164(19): 2162-2168.
-
(2004)
Arch Intern Med
, vol.164
, Issue.19
, pp. 2162-2168
-
-
Spencer, F.A.1
Fonarow, G.C.2
Frederick, P.D.3
-
20
-
-
0037177167
-
Withdrawal of statins increases event rates in patients with acute coronary syndromes
-
Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105(12): 1446-1452.
-
(2002)
Circulation
, vol.105
, Issue.12
, pp. 1446-1452
-
-
Heeschen, C.1
Hamm, C.W.2
Laufs, U.3
Snapinn, S.4
Bohm, M.5
White, H.D.6
-
21
-
-
36448964544
-
Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
-
Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007; 38(12): 3198-3204.
-
(2007)
Stroke
, vol.38
, Issue.12
, pp. 3198-3204
-
-
Amarenco, P.1
Goldstein, L.B.2
Szarek, M.3
-
22
-
-
0035936503
-
Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project
-
Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103(3): 387-392.
-
(2001)
Circulation
, vol.103
, Issue.3
, pp. 387-392
-
-
Byington, R.P.1
Davis, B.R.2
Plehn, J.F.3
-
23
-
-
3342996744
-
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study
-
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004; 110(4): 386-391.
-
(2004)
Circulation
, vol.110
, Issue.4
, pp. 386-391
-
-
Kinlay, S.1
Schwartz, G.G.2
Olsson, A.G.3
Rifai, N.4
Sasiela, W.J.5
Szarek, M.6
-
24
-
-
47649093893
-
The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery
-
Song YB, On YK, Kim JH, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 2008; 156(2): 373 e9-e16.
-
(2008)
Am Heart J
, vol.156
, Issue.2
-
-
Song, Y.B.1
On, Y.K.2
Kim, J.H.3
-
25
-
-
70349664405
-
Effects of rosuvastatin on atrial fibrillation occurrence: Ancillary results of the GISSI-HF trial
-
Maggioni AP, Fabbri G, Lucci D, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009; 30(19): 2327-2336.
-
(2009)
Eur Heart J
, vol.30
, Issue.19
, pp. 2327-2336
-
-
Maggioni, A.P.1
Fabbri, G.2
Lucci, D.3
-
26
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195-2207.
-
(2008)
N Engl J Med
, vol.359
, Issue.21
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
-
27
-
-
63849163945
-
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
-
Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360(14): 1395-1407.
-
(2009)
N Engl J Med
, vol.360
, Issue.14
, pp. 1395-1407
-
-
Fellstrom, B.C.1
Jardine, A.G.2
Schmieder, R.E.3
-
28
-
-
36549030340
-
Rosuvastatin in older patients with systolic heart failure
-
Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357(22): 2248-2261.
-
(2007)
N Engl J Med
, vol.357
, Issue.22
, pp. 2248-2261
-
-
Kjekshus, J.1
Apetrei, E.2
Barrios, V.3
-
30
-
-
65549127778
-
Statin islands and PPAR ligands in platelets
-
Phipps RP, Blumberg N. Statin islands and PPAR ligands in platelets. Arterioscler Thromb Vasc Biol 2009; 29(5): 620-621.
-
(2009)
Arterioscler Thromb Vasc Biol
, vol.29
, Issue.5
, pp. 620-621
-
-
Phipps, R.P.1
Blumberg, N.2
-
31
-
-
78049243976
-
Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor gamma
-
Shen Y, Wu H, Wang C, et al. Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor gamma. Eur J Pharmacol 2010; 649(1-3): 255-262.
-
(2010)
Eur J Pharmacol
, vol.649
, Issue.1-3
, pp. 255-262
-
-
Shen, Y.1
Wu, H.2
Wang, C.3
-
32
-
-
0035806626
-
Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
-
Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286(1): 64-70.
-
(2001)
JAMA
, vol.286
, Issue.1
, pp. 64-70
-
-
Albert, M.A.1
Danielson, E.2
Rifai, N.3
Ridker, P.M.4
-
33
-
-
18944381282
-
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia
-
Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005; 45(10): 1649-1653.
-
(2005)
J Am Coll Cardiol
, vol.45
, Issue.10
, pp. 1649-1653
-
-
Koh, K.K.1
Quon, M.J.2
Han, S.H.3
-
34
-
-
69549086473
-
Niacin: A re-emerging pharmaceutical for the treatment of dyslipidaemia
-
Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol 2009; 158(2): 429-441.
-
(2009)
Br J Pharmacol
, vol.158
, Issue.2
, pp. 429-441
-
-
Vosper, H.1
-
36
-
-
0032508533
-
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
-
Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273(37): 24266-24271.
-
(1998)
J Biol Chem
, vol.273
, Issue.37
, pp. 24266-24271
-
-
Laufs, U.1
Liao, J.K.2
-
37
-
-
23244457776
-
Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells
-
Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005; 112(5): 720-726.
-
(2005)
Circulation
, vol.112
, Issue.5
, pp. 720-726
-
-
Sen-Banerjee, S.1
Mir, S.2
Lin, Z.3
Hamik, A.4
Atkins, G.B.5
Das, H.6
-
38
-
-
36348930445
-
Statin treatment and 3' polyadenylation of eNOS mRNA
-
Kosmidou I, Moore JP, Weber M, Searles CD. Statin treatment and 3' polyadenylation of eNOS mRNA. Arterioscler Thromb Vasc Biol 2007; 27(12): 2642-2649.
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, Issue.12
, pp. 2642-2649
-
-
Kosmidou, I.1
Moore, J.P.2
Weber, M.3
Searles, C.D.4
-
39
-
-
0035830412
-
Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance
-
Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103(1): 113-118.
-
(2001)
Circulation
, vol.103
, Issue.1
, pp. 113-118
-
-
Feron, O.1
Dessy, C.2
Desager, J.P.3
Balligand, J.L.4
-
40
-
-
0035834823
-
Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins
-
Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001; 89(10): 866-873.
-
(2001)
Circ Res
, vol.89
, Issue.10
, pp. 866-873
-
-
Brouet, A.1
Sonveaux, P.2
Dessy, C.3
Moniotte, S.4
Balligand, J.L.5
Feron, O.6
-
41
-
-
79959712024
-
Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis
-
Antoniades C, Demosthenous M, Tousoulis D, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 2011; 58(1): 93-98.
-
(2011)
Hypertension
, vol.58
, Issue.1
, pp. 93-98
-
-
Antoniades, C.1
Demosthenous, M.2
Tousoulis, D.3
-
42
-
-
65949123566
-
Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: Implications for endothelial function in human atherosclerosis
-
Antoniades C, Shirodaria C, Leeson P, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J 2009; 30(9): 1142-1150.
-
(2009)
Eur Heart J
, vol.30
, Issue.9
, pp. 1142-1150
-
-
Antoniades, C.1
Shirodaria, C.2
Leeson, P.3
-
43
-
-
33846604213
-
Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus
-
Tousoulis D, Antoniades C, Vasiliadou C, et al. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart 2007; 93(2): 244-246.
-
(2007)
Heart
, vol.93
, Issue.2
, pp. 244-246
-
-
Tousoulis, D.1
Antoniades, C.2
Vasiliadou, C.3
-
44
-
-
3142606890
-
Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia
-
Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004; 94(2): 157-161.
-
(2004)
Am J Cardiol
, vol.94
, Issue.2
, pp. 157-161
-
-
Lu, T.M.1
Ding, Y.A.2
Leu, H.B.3
Yin, W.H.4
Sheu, W.H.5
Chu, K.M.6
-
45
-
-
79952395245
-
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients
-
Nishiyama Y, Ueda M, Otsuka T, et al. Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients. J Atheroscler Thromb 2011; 18(2): 131-137.
-
(2011)
J Atheroscler Thromb
, vol.18
, Issue.2
, pp. 131-137
-
-
Nishiyama, Y.1
Ueda, M.2
Otsuka, T.3
-
46
-
-
73549110255
-
Regulation of the ADMA-DDAH system in endothelial cells: A novel mechanism for the sterol response element binding proteins, SREBP1c and -2
-
Ivashchenko CY, Bradley BT, Ao Z, Leiper J, Vallance P, Johns DG. Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2. Am J Physiol Heart Circ Physiol 2010; 298(1): H251-H258.
-
(2010)
Am J Physiol Heart Circ Physiol
, vol.298
, Issue.1
-
-
Ivashchenko, C.Y.1
Bradley, B.T.2
Ao, Z.3
Leiper, J.4
Vallance, P.5
Johns, D.G.6
-
47
-
-
37349021748
-
Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation
-
Antoniades C, Shirodaria C, Crabtree M, et al. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 2007; 116(24): 2851-9.
-
(2007)
Circulation
, vol.116
, Issue.24
, pp. 2851-2859
-
-
Antoniades, C.1
Shirodaria, C.2
Crabtree, M.3
-
48
-
-
0345532411
-
HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells
-
Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23(2): 176-182.
-
(2003)
Arterioscler Thromb Vasc Biol
, vol.23
, Issue.2
, pp. 176-182
-
-
Hattori, Y.1
Nakanishi, N.2
Akimoto, K.3
Yoshida, M.4
Kasai, K.5
-
49
-
-
1442302282
-
Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries
-
Matsuno H, Takei M, Hayashi H, Nakajima K, Ishisaki A, Kozawa O. Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. J Cardiovasc Pharmacol 2004; 43(3): 333-340.
-
(2004)
J Cardiovasc Pharmacol
, vol.43
, Issue.3
, pp. 333-340
-
-
Matsuno, H.1
Takei, M.2
Hayashi, H.3
Nakajima, K.4
Ishisaki, A.5
Kozawa, O.6
-
50
-
-
78650827558
-
Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress
-
Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis 2011; 214(1): 151-157.
-
(2011)
Atherosclerosis
, vol.214
, Issue.1
, pp. 151-157
-
-
Tousoulis, D.1
Andreou, I.2
Tsiatas, M.3
-
51
-
-
0034607119
-
Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC
-
Takeuchi S, Kawashima S, Rikitake Y, et al. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem Biophys Res Commun 2000; 269(1): 97-102.
-
(2000)
Biochem Biophys Res Commun
, vol.269
, Issue.1
, pp. 97-102
-
-
Takeuchi, S.1
Kawashima, S.2
Rikitake, Y.3
-
52
-
-
34547492326
-
Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues
-
Fish RJ, Yang H, Viglino C, Schorer R, Dunoyer-Geindre S, Kruithof EK. Fluvastatin inhibits regulated secretion of endothelial cell von Willebrand factor in response to diverse secretagogues. Biochem J 2007; 405(3): 597-604.
-
(2007)
Biochem J
, vol.405
, Issue.3
, pp. 597-604
-
-
Fish, R.J.1
Yang, H.2
Viglino, C.3
Schorer, R.4
Dunoyer-Geindre, S.5
Kruithof, E.K.6
-
53
-
-
77950008071
-
Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: Anti-angiogenic actions possibly contributing to plaque stability
-
Massaro M, Zampolli A, Scoditti E, et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res 2010; 86(2): 311-320.
-
(2010)
Cardiovasc Res
, vol.86
, Issue.2
, pp. 311-320
-
-
Massaro, M.1
Zampolli, A.2
Scoditti, E.3
-
54
-
-
0032757209
-
Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells
-
Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147(2): 253-261.
-
(1999)
Atherosclerosis
, vol.147
, Issue.2
, pp. 253-261
-
-
Ortego, M.1
Bustos, C.2
Hernandez-Presa, M.A.3
-
55
-
-
62249109402
-
Targeting redox signaling in the vascular wall: From basic science to clinical practice
-
Antoniades C, Antonopoulos AS, Bendall JK, Channon KM. Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr Pharm Des 2009; 15(3): 329-342.
-
(2009)
Curr Pharm Des
, vol.15
, Issue.3
, pp. 329-342
-
-
Antoniades, C.1
Antonopoulos, A.S.2
Bendall, J.K.3
Channon, K.M.4
-
56
-
-
0142070772
-
Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin
-
Haloui M, Meilhac O, Jandrot-Perrus M, Michel JB. Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin. Eur J Pharmacol 2003; 474(2-3): 175-184.
-
(2003)
Eur J Pharmacol
, vol.474
, Issue.2-3
, pp. 175-184
-
-
Haloui, M.1
Meilhac, O.2
Jandrot-Perrus, M.3
Michel, J.B.4
-
57
-
-
18144418144
-
Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels
-
Turner NA, O'Regan DJ, Ball SG, Porter KE. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J 2005; 19(7): 804-806.
-
(2005)
FASEB J
, vol.19
, Issue.7
, pp. 804-806
-
-
Turner, N.A.1
O'Regan, D.J.2
Ball, S.G.3
Porter, K.E.4
-
58
-
-
34547631574
-
HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: Role of RhoA/ROCK and MAPK pathways
-
Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 2007; 50(2): 377-383.
-
(2007)
Hypertension
, vol.50
, Issue.2
, pp. 377-383
-
-
Ruperez, M.1
Rodrigues-Diez, R.2
Blanco-Colio, L.M.3
-
59
-
-
0032248147
-
Geranylgeranylpyrophosphate plays a key role for the G1 to S transition in vascular smooth muscle cells
-
Terano T, Shiina T, Noguchi Y, et al. Geranylgeranylpyrophosphate plays a key role for the G1 to S transition in vascular smooth muscle cells. J Atheroscler Thromb 1998; 5(1): 1-6.
-
(1998)
J Atheroscler Thromb
, vol.5
, Issue.1
, pp. 1-6
-
-
Terano, T.1
Shiina, T.2
Noguchi, Y.3
-
60
-
-
0033003112
-
Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration
-
Komukai M, Wajima YS, Tashiro J, Shinomiya M, Saito Y, Morisaki N. Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration. Scand J Clin Lab Invest 1999; 59(3): 159-166.
-
(1999)
Scand J Clin Lab Invest
, vol.59
, Issue.3
, pp. 159-166
-
-
Komukai, M.1
Wajima, Y.S.2
Tashiro, J.3
Shinomiya, M.4
Saito, Y.5
Morisaki, N.6
-
61
-
-
0037667687
-
Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2
-
Yamakawa T, Tanaka S, Kamei J, Kadonosono K, Okuda K. Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2. J Atheroscler Thromb 2003; 10(1): 37-42.
-
(2003)
J Atheroscler Thromb
, vol.10
, Issue.1
, pp. 37-42
-
-
Yamakawa, T.1
Tanaka, S.2
Kamei, J.3
Kadonosono, K.4
Okuda, K.5
-
62
-
-
33751166173
-
Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia
-
Umeji K, Umemoto S, Itoh S, et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol Heart Circ Physiol 2006; 291(5): H2522-H2532.
-
(2006)
Am J Physiol Heart Circ Physiol
, vol.291
, Issue.5
-
-
Umeji, K.1
Umemoto, S.2
Itoh, S.3
-
63
-
-
4644305196
-
Modulation of oxidant and antioxidant enzyme expression and function in vascular cells
-
Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 2004; 44(4): 381-386.
-
(2004)
Hypertension
, vol.44
, Issue.4
, pp. 381-386
-
-
Wassmann, S.1
Wassmann, K.2
Nickenig, G.3
-
64
-
-
4143102291
-
Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: A novel vasculoprotective function of statins
-
Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004; 110(7): 856-861.
-
(2004)
Circulation
, vol.110
, Issue.7
, pp. 856-861
-
-
Haendeler, J.1
Hoffmann, J.2
Zeiher, A.M.3
Dimmeler, S.4
-
65
-
-
36349008676
-
Statin-mediated cytoprotection of human vascular endothelial cells: A role for Kruppel-like factor 2-dependent induction of heme oxygenase-1
-
Ali F, Hamdulay SS, Kinderlerer AR, et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 2007; 5(12): 2537-2546.
-
(2007)
J Thromb Haemost
, vol.5
, Issue.12
, pp. 2537-2546
-
-
Ali, F.1
Hamdulay, S.S.2
Kinderlerer, A.R.3
-
66
-
-
0032478236
-
Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia
-
Simons LA, Sullivan D, Simons J, Celermajer DS. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis 1998; 137(1): 197-203.
-
(1998)
Atherosclerosis
, vol.137
, Issue.1
, pp. 197-203
-
-
Simons, L.A.1
Sullivan, D.2
Simons, J.3
Celermajer, D.S.4
-
67
-
-
0033862040
-
Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: A double-blind study
-
Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000; 36(2): 410-416.
-
(2000)
J Am Coll Cardiol
, vol.36
, Issue.2
, pp. 410-416
-
-
Mullen, M.J.1
Wright, D.2
Donald, A.E.3
Thorne, S.4
Thomson, H.5
Deanfield, J.E.6
-
68
-
-
10844242066
-
Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure
-
Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 2005; 91(1): 27-31.
-
(2005)
Heart
, vol.91
, Issue.1
, pp. 27-31
-
-
Tousoulis, D.1
Antoniades, C.2
Bosinakou, E.3
-
69
-
-
79955523320
-
Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures
-
Loppnow H, Zhang L, Buerke M, et al. Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med 2011; 15(4): 994-1004.
-
(2011)
J Cell Mol Med
, vol.15
, Issue.4
, pp. 994-1004
-
-
Loppnow, H.1
Zhang, L.2
Buerke, M.3
-
70
-
-
40949143105
-
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells
-
Mausner-Fainberg K, Luboshits G, Mor A, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008; 197(2): 829-839.
-
(2008)
Atherosclerosis
, vol.197
, Issue.2
, pp. 829-839
-
-
Mausner-Fainberg, K.1
Luboshits, G.2
Mor, A.3
-
71
-
-
77949657991
-
Modulation of human T cells signaling transduction by lovastatin
-
Cheng SM, Lai JH, Yang SP, et al. Modulation of human T cells signaling transduction by lovastatin. Int J Cardiol 2010; 140(1): 24-33.
-
(2010)
Int J Cardiol
, vol.140
, Issue.1
, pp. 24-33
-
-
Cheng, S.M.1
Lai, J.H.2
Yang, S.P.3
-
72
-
-
0029031569
-
Lovastatin inhibits proliferation and differentiation and causes apoptosis in lipopolysaccharide-stimulated murine B cells
-
Reedquist KA, Pope TK, Roess DA. Lovastatin inhibits proliferation and differentiation and causes apoptosis in lipopolysaccharide-stimulated murine B cells. Biochem Biophys Res Commun 1995; 211(2): 665-670.
-
(1995)
Biochem Biophys Res Commun
, vol.211
, Issue.2
, pp. 665-670
-
-
Reedquist, K.A.1
Pope, T.K.2
Roess, D.A.3
-
73
-
-
0242349750
-
Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins
-
Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 2003; 108(17): 2113-2120.
-
(2003)
Circulation
, vol.108
, Issue.17
, pp. 2113-2120
-
-
Shimizu, K.1
Aikawa, M.2
Takayama, K.3
Libby, P.4
Mitchell, R.N.5
-
74
-
-
0036066345
-
Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients
-
Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22(7): 1194-1199.
-
(2002)
Arterioscler Thromb Vasc Biol
, vol.22
, Issue.7
, pp. 1194-1199
-
-
Rezaie-Majd, A.1
Maca, T.2
Bucek, R.A.3
-
75
-
-
33845522700
-
Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes
-
Bruegel M, Teupser D, Haffner I, Mueller M, Thiery J. Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. Clin Exp Pharmacol Physiol 2006; 33(12): 1144-1149.
-
(2006)
Clin Exp Pharmacol Physiol
, vol.33
, Issue.12
, pp. 1144-1149
-
-
Bruegel, M.1
Teupser, D.2
Haffner, I.3
Mueller, M.4
Thiery, J.5
-
76
-
-
68249124819
-
The CD40/CD40 ligand system: Linking inflammation with atherothrombosis
-
Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54(8): 669-677.
-
(2009)
J Am Coll Cardiol
, vol.54
, Issue.8
, pp. 669-677
-
-
Antoniades, C.1
Bakogiannis, C.2
Tousoulis, D.3
Antonopoulos, A.S.4
Stefanadis, C.5
-
77
-
-
15744369717
-
CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: Inhibitory effects of atorvastatin
-
Mosheimer BA, Kaneider NC, Feistritzer C, et al. CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin. Blood Coagul Fibrinolysis 2005; 16(2): 105-110.
-
(2005)
Blood Coagul Fibrinolysis
, vol.16
, Issue.2
, pp. 105-110
-
-
Mosheimer, B.A.1
Kaneider, N.C.2
Feistritzer, C.3
-
78
-
-
33747884357
-
Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells
-
Jiang M, Bujo H, Zhu Y, et al. Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells. Biochem Biophys Res Commun 2006; 348(4): 1367-1377.
-
(2006)
Biochem Biophys Res Commun
, vol.348
, Issue.4
, pp. 1367-1377
-
-
Jiang, M.1
Bujo, H.2
Zhu, Y.3
-
79
-
-
0036072088
-
Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: Effects on Rho-GTPase and adenosine nucleotide metabolism
-
Kaneider NC, Egger P, Dunzendorfer S, et al. Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism. Arterioscler Thromb Vasc Biol 2002; 22(6): 894-900.
-
(2002)
Arterioscler Thromb Vasc Biol
, vol.22
, Issue.6
, pp. 894-900
-
-
Kaneider, N.C.1
Egger, P.2
Dunzendorfer, S.3
-
80
-
-
34249293701
-
Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: Possible improvement of intraplatelet redox imbalance via HMG-CoA reductase
-
Haramaki N, Ikeda H, Takenaka K, et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 2007; 27(6): 1471-1477.
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, Issue.6
, pp. 1471-1477
-
-
Haramaki, N.1
Ikeda, H.2
Takenaka, K.3
-
81
-
-
13244289761
-
Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients
-
Puccetti L, Sawamura T, Pasqui AL, Pastorelli M, Auteri A, Bruni F. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients. Eur J Clin Invest 2005; 35(1): 47-51.
-
(2005)
Eur J Clin Invest
, vol.35
, Issue.1
, pp. 47-51
-
-
Puccetti, L.1
Sawamura, T.2
Pasqui, A.L.3
Pastorelli, M.4
Auteri, A.5
Bruni, F.6
-
82
-
-
69849105377
-
Inhibition of platelet-rich arterial thrombus in vivo: Acute antithrombotic effect of intravenous HMG-CoA reductase therapy
-
Obi C, Wysokinski W, Karnicki K, Owen WG, McBane RD. Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscler Thromb Vasc Biol 2009; 29(9): 1271-1276.
-
(2009)
Arterioscler Thromb Vasc Biol
, vol.29
, Issue.9
, pp. 1271-1276
-
-
Obi, C.1
Wysokinski, W.2
Karnicki, K.3
Owen, W.G.4
McBane, R.D.5
-
83
-
-
79960048075
-
Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology
-
Yla-Herttuala S, Bentzon JF, Daemen M, et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost 2011; 106(1): 1-19.
-
(2011)
Thromb Haemost
, vol.106
, Issue.1
, pp. 1-19
-
-
Yla-Herttuala, S.1
Bentzon, J.F.2
Daemen, M.3
-
84
-
-
0035916233
-
Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization
-
Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103(7): 926-933.
-
(2001)
Circulation
, vol.103
, Issue.7
, pp. 926-933
-
-
Crisby, M.1
Nordin-Fredriksson, G.2
Shah, P.K.3
Yano, J.4
Zhu, J.5
Nilsson, J.6
-
85
-
-
79951930958
-
Small leucine-rich proteoglycans in atherosclerotic lesions: Novel targets of chronic statin treatment?
-
Marzoll A, Melchior-Becker A, Cipollone F, Fischer JW. Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment? J Cell Mol Med 2011; 15(2): 232-243.
-
(2011)
J Cell Mol Med
, vol.15
, Issue.2
, pp. 232-243
-
-
Marzoll, A.1
Melchior-Becker, A.2
Cipollone, F.3
Fischer, J.W.4
-
86
-
-
0036869136
-
Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques
-
Stefanadis C, Toutouzas K, Vavuranakis M, et al. Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques. Eur Heart J 2002; 23(21): 1664-1669.
-
(2002)
Eur Heart J
, vol.23
, Issue.21
, pp. 1664-1669
-
-
Stefanadis, C.1
Toutouzas, K.2
Vavuranakis, M.3
-
87
-
-
77953042905
-
Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis
-
Zhang A, Zhang H, Wu S. Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis. Inflamm Res 2010; 59(4): 255-262.
-
(2010)
Inflamm Res
, vol.59
, Issue.4
, pp. 255-262
-
-
Zhang, A.1
Zhang, H.2
Wu, S.3
-
88
-
-
60549084918
-
Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction
-
Stumpf C, Petzi S, Seybold K, et al. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin Sci (Lond) 2009; 116(1): 45-52.
-
(2009)
Clin Sci (Lond)
, vol.116
, Issue.1
, pp. 45-52
-
-
Stumpf, C.1
Petzi, S.2
Seybold, K.3
-
89
-
-
0038825370
-
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats
-
Hasegawa H, Yamamoto R, Takano H, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003; 35(8): 953-960.
-
(2003)
J Mol Cell Cardiol
, vol.35
, Issue.8
, pp. 953-960
-
-
Hasegawa, H.1
Yamamoto, R.2
Takano, H.3
-
90
-
-
0141841614
-
Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment
-
Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003; 108(13): 1567-1574.
-
(2003)
Circulation
, vol.108
, Issue.13
, pp. 1567-1574
-
-
Maack, C.1
Kartes, T.2
Kilter, H.3
-
91
-
-
40949120630
-
Apoptosis contributes to septic cardiomyopathy and is improved by simvastatin therapy
-
Buerke U, Carter JM, Schlitt A, et al. Apoptosis contributes to septic cardiomyopathy and is improved by simvastatin therapy. Shock 2008; 29(4): 497-503.
-
(2008)
Shock
, vol.29
, Issue.4
, pp. 497-503
-
-
Buerke, U.1
Carter, J.M.2
Schlitt, A.3
-
92
-
-
67650220186
-
Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction
-
Vilahur G, Casani L, Pena E, Duran X, Juan-Babot O, Badimon L. Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. Atherosclerosis 2009; 206(1): 95-101.
-
(2009)
Atherosclerosis
, vol.206
, Issue.1
, pp. 95-101
-
-
Vilahur, G.1
Casani, L.2
Pena, E.3
Duran, X.4
Juan-Babot, O.5
Badimon, L.6
-
93
-
-
62449222305
-
Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins
-
Yang Y, Mou Y, Hu SJ, Fu M. Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins. Eur J Heart Fail 2009; 11(1): 6-13.
-
(2009)
Eur J Heart Fail
, vol.11
, Issue.1
, pp. 6-13
-
-
Yang, Y.1
Mou, Y.2
Hu, S.J.3
Fu, M.4
-
94
-
-
28344437151
-
Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction
-
Cheng X, Liao YH, Zhang J, et al. Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction. Eur J Heart Fail 2005; 7(7): 1099-1104.
-
(2005)
Eur J Heart Fail
, vol.7
, Issue.7
, pp. 1099-1104
-
-
Cheng, X.1
Liao, Y.H.2
Zhang, J.3
-
95
-
-
80052602720
-
Atrial Sources of Reactive Oxygen Species Vary With the Duration and Substrate of Atrial Fibrillation: Implications for the Antiarrhythmic Effect of Statins
-
Reilly SN, Jayaram R, Nahar K, et al. Atrial Sources of Reactive Oxygen Species Vary With the Duration and Substrate of Atrial Fibrillation: Implications for the Antiarrhythmic Effect of Statins. Circulation 2011.
-
(2011)
Circulation
-
-
Reilly, S.N.1
Jayaram, R.2
Nahar, K.3
-
96
-
-
77957778832
-
Atorvastatin treatment affects atrial ion currents and their tachycardia-induced remodeling in rabbits
-
Laszlo R, Menzel KA, Bentz K, et al. Atorvastatin treatment affects atrial ion currents and their tachycardia-induced remodeling in rabbits. Life Sci 2010; 87(15-16): 507-513.
-
(2010)
Life Sci
, vol.87
, Issue.15-16
, pp. 507-513
-
-
Laszlo, R.1
Menzel, K.A.2
Bentz, K.3
-
97
-
-
70349305709
-
Targeting eNOS and beyond: Emerging heterogeneity of the role of endothelial Rho proteins in stroke protection
-
Sawada N, Liao JK. Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. Expert Rev Neurother 2009; 9(8): 1171-1186.
-
(2009)
Expert Rev Neurother
, vol.9
, Issue.8
, pp. 1171-1186
-
-
Sawada, N.1
Liao, J.K.2
-
98
-
-
0037189048
-
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice
-
Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002; 942(1-2): 23-30.
-
(2002)
Brain Res
, vol.942
, Issue.1-2
, pp. 23-30
-
-
Laufs, U.1
Gertz, K.2
Dirnagl, U.3
Bohm, M.4
Nickenig, G.5
Endres, M.6
-
99
-
-
0037038402
-
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
-
Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420(6911): 78-84.
-
(2002)
Nature
, vol.420
, Issue.6911
, pp. 78-84
-
-
Youssef, S.1
Stuve, O.2
Patarroyo, J.C.3
Ruiz, P.J.4
Radosevich, J.L.5
Hur, E.M.6
-
100
-
-
0037309378
-
A novel anti-inflammatory role for simvastatin in inflammatory arthritis
-
Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170(3): 1524-1530.
-
(2003)
J Immunol
, vol.170
, Issue.3
, pp. 1524-1530
-
-
Leung, B.P.1
Sattar, N.2
Crilly, A.3
-
101
-
-
33750939673
-
RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: Inhibitory effect of simvastatin
-
Xu H, Liu P, Liang L, et al. RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 2006; 54(11): 3441-3451.
-
(2006)
Arthritis Rheum
, vol.54
, Issue.11
, pp. 3441-3451
-
-
Xu, H.1
Liu, P.2
Liang, L.3
-
102
-
-
79955652163
-
Geranylgeranyl-pyrophosphate regulates secretion of pentraxin 3 and monocyte chemoattractant protein-1 from rheumatoid fibroblast-like synoviocytes in distinct manners
-
Yokota K, Miyoshi F, Sato K, Asanuma Y, Akiyama Y, Mimura T. Geranylgeranyl-pyrophosphate regulates secretion of pentraxin 3 and monocyte chemoattractant protein-1 from rheumatoid fibroblast-like synoviocytes in distinct manners. Clin Exp Rheumatol 2011; 29(1): 43-9.
-
(2011)
Clin Exp Rheumatol
, vol.29
, Issue.1
, pp. 43-49
-
-
Yokota, K.1
Miyoshi, F.2
Sato, K.3
Asanuma, Y.4
Akiyama, Y.5
Mimura, T.6
-
103
-
-
0027987849
-
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
-
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-1389.
-
(1994)
Lancet
, vol.344
, Issue.8934
, pp. 1383-1389
-
-
-
104
-
-
0037132607
-
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
-
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288(23): 2998-3007.
-
(2002)
JAMA
, vol.288
, Issue.23
, pp. 2998-3007
-
-
-
105
-
-
0037031061
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized place bo-controlled trial
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised place bo-controlled trial. Lancet 2002; 360(9326): 7-22.
-
(2002)
Lancet
, vol.360
, Issue.9326
, pp. 7-22
-
-
-
106
-
-
11144355354
-
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
-
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495-1504.
-
(2004)
N Engl J Med
, vol.350
, Issue.15
, pp. 1495-1504
-
-
Cannon, C.P.1
Braunwald, E.2
McCabe, C.H.3
-
107
-
-
4544243333
-
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial
-
de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292(11): 1307-1316.
-
(2004)
JAMA
, vol.292
, Issue.11
, pp. 1307-1316
-
-
de Lemos, J.A.1
Blazing, M.A.2
Wiviott, S.D.3
-
108
-
-
37549020283
-
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study
-
Kinlay S, Schwartz GG, Olsson AG, et al. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol 2008; 28(1): 142-147.
-
(2008)
Arterioscler Thromb Vasc Biol
, vol.28
, Issue.1
, pp. 142-147
-
-
Kinlay, S.1
Schwartz, G.G.2
Olsson, A.G.3
-
109
-
-
15944410609
-
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
-
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425-1435.
-
(2005)
N Engl J Med
, vol.352
, Issue.14
, pp. 1425-1435
-
-
Larosa, J.C.1
Grundy, S.M.2
Waters, D.D.3
-
110
-
-
0037178569
-
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial
-
Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287(24): 3215-3222.
-
(2002)
JAMA
, vol.287
, Issue.24
, pp. 3215-3222
-
-
Serruys, P.W.1
de Feyter, P.2
Macaya, C.3
-
111
-
-
0032904753
-
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial
-
Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999; 20(1): 58-69.
-
(1999)
Eur Heart J
, vol.20
, Issue.1
, pp. 58-69
-
-
Serruys, P.W.1
Foley, D.P.2
Jackson, G.3
-
112
-
-
0037420492
-
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
-
Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
-
(2003)
Lancet
, vol.361
, Issue.9364
, pp. 1149-1158
-
-
Sever, P.S.1
Dahlof, B.2
Poulter, N.R.3
-
113
-
-
0343273397
-
Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration
-
Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995; 346(8991-8992): 1647-1653.
-
(1995)
Lancet
, vol.346
, Issue.8991-8992
, pp. 1647-1653
-
-
-
114
-
-
0141841612
-
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study
-
Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108(13): 1560-1566.
-
(2003)
Circulation
, vol.108
, Issue.13
, pp. 1560-1566
-
-
Kinlay, S.1
Schwartz, G.G.2
Olsson, A.G.3
-
115
-
-
85027938156
-
Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction
-
Sposito AC, Santos SN, de Faria EC, et al. Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction. Arterioscler Thromb Vasc Biol 2011; 31(5): 1240-1246.
-
(2011)
Arterioscler Thromb Vasc Biol
, vol.31
, Issue.5
, pp. 1240-1246
-
-
Sposito, A.C.1
Santos, S.N.2
de Faria, E.C.3
-
116
-
-
67651033611
-
Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial
-
Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009; 54(6): 558-565.
-
(2009)
J Am Coll Cardiol
, vol.54
, Issue.6
, pp. 558-565
-
-
Di Sciascio, G.1
Patti, G.2
Pasceri, V.3
Gaspardone, A.4
Colonna, G.5
Montinaro, A.6
-
118
-
-
78651287065
-
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >/= 5% or Framingham risk >20%: Post hoc analyses of the JUPITER trial requested by European health authorities
-
Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >/= 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J 2011; 32(1): 75-83.
-
(2011)
Eur Heart J
, vol.32
, Issue.1
, pp. 75-83
-
-
Koenig, W.1
Ridker, P.M.2
-
119
-
-
79551682546
-
C-reactive protein concentration and the vascular benefits of statin therapy: An analysis of 20,536 patients in the Heart Protection Study
-
Jonathan E, Derrick B, Emma L, et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 2011; 377(9764): 469-476.
-
(2011)
Lancet
, vol.377
, Issue.9764
, pp. 469-476
-
-
Jonathan, E.1
Derrick, B.2
Emma, L.3
-
120
-
-
0041431121
-
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy
-
Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108(7): 839-843.
-
(2003)
Circulation
, vol.108
, Issue.7
, pp. 839-843
-
-
Node, K.1
Fujita, M.2
Kitakaze, M.3
Hori, M.4
Liao, J.K.5
-
121
-
-
20844462717
-
Effect of pravastatin on cardiovascular events in people with chronic kidney disease
-
Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110(12): 1557-1563.
-
(2004)
Circulation
, vol.110
, Issue.12
, pp. 1557-1563
-
-
Tonelli, M.1
Isles, C.2
Curhan, G.C.3
-
122
-
-
77949332406
-
Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: A secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial
-
Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010; 55(12): 1266-1273.
-
(2010)
J Am Coll Cardiol
, vol.55
, Issue.12
, pp. 1266-1273
-
-
Ridker, P.M.1
Macfadyen, J.2
Cressman, M.3
Glynn, R.J.4
-
123
-
-
33748358833
-
Statins in the treatment of chronic heart failure: A systematic review
-
van der Harst P, Voors AA, van Gilst WH, Bohm M, van Veldhuisen DJ. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 2006; 3(8): e333.
-
(2006)
PLoS Med
, vol.3
, Issue.8
-
-
van der Harst, P.1
Voors, A.A.2
van Gilst, W.H.3
Bohm, M.4
van Veldhuisen, D.J.5
-
124
-
-
77950584849
-
Statin therapy for low-LDL, high-hsCRP patients: From JUPITER to CORONA
-
Ridker PM. Statin therapy for low-LDL, high-hsCRP patients: from JUPITER to CORONA. Clin Chem 2010; 56(4): 505-507.
-
(2010)
Clin Chem
, vol.56
, Issue.4
, pp. 505-507
-
-
Ridker, P.M.1
-
125
-
-
73349137973
-
Rosuvastatin along the cardiovascular continuum: From JUPITER to AURORA
-
Barrios V, Escobar C. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Rev Cardiovasc Ther 2009; 7(11): 1317-1327.
-
(2009)
Expert Rev Cardiovasc Ther
, vol.7
, Issue.11
, pp. 1317-1327
-
-
Barrios, V.1
Escobar, C.2
-
126
-
-
77950304018
-
Rosuvastatin and cardiovascular continuum when time is important
-
author reply 6
-
Barrios V, Escobar C. Rosuvastatin and cardiovascular continuum when time is important. J Am Coll Cardiol 2010; 55(15): 1645-1646; author reply 6.
-
(2010)
J Am Coll Cardiol
, vol.55
, Issue.15
, pp. 1645-1646
-
-
Barrios, V.1
Escobar, C.2
-
127
-
-
22344458137
-
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
-
Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353(3): 238-248.
-
(2005)
N Engl J Med
, vol.353
, Issue.3
, pp. 238-248
-
-
Wanner, C.1
Krane, V.2
Marz, W.3
-
128
-
-
79959746706
-
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial
-
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-2192.
-
(2011)
Lancet
, vol.377
, Issue.9784
, pp. 2181-2192
-
-
Baigent, C.1
Landray, M.J.2
Reith, C.3
Emberson, J.4
Wheeler, D.C.5
Tomson, C.6
-
129
-
-
0034687606
-
Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription
-
Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000; 102(25): 3104-3110.
-
(2000)
Circulation
, vol.102
, Issue.25
, pp. 3104-3110
-
-
Laufs, U.1
Endres, M.2
Custodis, F.3
-
130
-
-
13844267374
-
Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: An effect independent on cholesterol elevation
-
Lai WT, Lee KT, Chu CS, et al. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation. Int J Cardiol 2005; 98(3): 459-464.
-
(2005)
Int J Cardiol
, vol.98
, Issue.3
, pp. 459-464
-
-
Lai, W.T.1
Lee, K.T.2
Chu, C.S.3
-
131
-
-
70350572370
-
Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal
-
Sposito AC, Carvalho LS, Cintra RM, et al. Rebound inflammatory response during the acute phase of myocardial infarction after simvastatin withdrawal. Atherosclerosis 2009; 207(1): 191-194.
-
(2009)
Atherosclerosis
, vol.207
, Issue.1
, pp. 191-194
-
-
Sposito, A.C.1
Carvalho, L.S.2
Cintra, R.M.3
-
132
-
-
33748972259
-
Rebound of inflammatory response after withdrawal of statins does not increases event rates in patients with stable cardiac disease
-
Hu CL, Li YB, Huang CX. Rebound of inflammatory response after withdrawal of statins does not increases event rates in patients with stable cardiac disease. Med Hypotheses 2006; 67(6): 1466-1467.
-
(2006)
Med Hypotheses
, vol.67
, Issue.6
, pp. 1466-1467
-
-
Hu, C.L.1
Li, Y.B.2
Huang, C.X.3
-
133
-
-
34447251828
-
Effect of statin withdrawal on frequency of cardiac events after vascular surgery
-
Schouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007; 100(2): 316-320.
-
(2007)
Am J Cardiol
, vol.100
, Issue.2
, pp. 316-320
-
-
Schouten, O.1
Hoeks, S.E.2
Welten, G.M.3
-
134
-
-
34548278923
-
Statin treatment withdrawal in ischemic stroke: A controlled randomized study
-
Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69(9): 904-910.
-
(2007)
Neurology
, vol.69
, Issue.9
, pp. 904-910
-
-
Blanco, M.1
Nombela, F.2
Castellanos, M.3
-
135
-
-
36949033817
-
Emerging indications for statins: A pluripotent family of agents with several potential applications
-
Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des 2007; 13(35): 3622-3636.
-
(2007)
Curr Pharm Des
, vol.13
, Issue.35
, pp. 3622-3636
-
-
Paraskevas, K.I.1
Tzovaras, A.A.2
Briana, D.D.3
Mikhailidis, D.P.4
-
136
-
-
80051796539
-
Graft-Protective Effects of the HMG-CoA Reductase Inhibitor Pravastatin After Lung Transplantation-A Propensity Score Analysis With 23 Years of Follow-Up
-
Li Y, Gottlieb J, Ma D, et al. Graft-Protective Effects of the HMG-CoA Reductase Inhibitor Pravastatin After Lung Transplantation-A Propensity Score Analysis With 23 Years of Follow-Up. Transplantation 2011; 92(4): 486-492.
-
(2011)
Transplantation
, vol.92
, Issue.4
, pp. 486-492
-
-
Li, Y.1
Gottlieb, J.2
Ma, D.3
-
137
-
-
36849065762
-
Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: Preliminary findings
-
di Pasquale P, Cannizzaro S, Fasullo S, et al. Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings. Clin Sci (Lond) 2007; 113(11): 443-448.
-
(2007)
Clin Sci (Lond)
, vol.113
, Issue.11
, pp. 443-448
-
-
di Pasquale, P.1
Cannizzaro, S.2
Fasullo, S.3
-
138
-
-
77954688218
-
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy
-
Lanzillo R, Orefice G, Quarantelli M, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 2010; 16(4): 450-454.
-
(2010)
Mult Scler
, vol.16
, Issue.4
, pp. 450-454
-
-
Lanzillo, R.1
Orefice, G.2
Quarantelli, M.3
-
139
-
-
33645305976
-
Statins in rheumatology
-
Soubrier M, Roux C. Statins in rheumatology. Joint Bone Spine 2006; 73(2): 159-168.
-
(2006)
Joint Bone Spine
, vol.73
, Issue.2
, pp. 159-168
-
-
Soubrier, M.1
Roux, C.2
-
140
-
-
0036264588
-
Cardiovascular disease and osteoporosis: Is there a link between lipids and bone?
-
Burnett JR, Vasikaran SD. Cardiovascular disease and osteoporosis: is there a link between lipids and bone? Ann Clin Biochem 2002; 39(Pt 3): 203-210.
-
(2002)
Ann Clin Biochem
, vol.39
, Issue.Pt 3
, pp. 203-210
-
-
Burnett, J.R.1
Vasikaran, S.D.2
-
141
-
-
77953802713
-
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases
-
Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010; 8(4): 437-449.
-
(2010)
Curr Vasc Pharmacol
, vol.8
, Issue.4
, pp. 437-449
-
-
Gasparyan, A.Y.1
Stavropoulos-Kalinoglou, A.2
Mikhailidis, D.P.3
Toms, T.E.4
Douglas, K.M.5
Kitas, G.D.6
-
142
-
-
84857047906
-
The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: A comprehensive review
-
Mihos CG, Artola RT, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int 2012; 32(2): 287-294.
-
(2012)
Rheumatol Int
, vol.32
, Issue.2
, pp. 287-294
-
-
Mihos, C.G.1
Artola, R.T.2
Santana, O.3
-
143
-
-
34247230923
-
Effects of pravastatin in murine collagen-induced arthritis
-
Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int 2007; 27(7): 631-639.
-
(2007)
Rheumatol Int
, vol.27
, Issue.7
, pp. 631-639
-
-
Yamagata, T.1
Kinoshita, K.2
Nozaki, Y.3
Sugiyama, M.4
Ikoma, S.5
Funauchi, M.6
-
144
-
-
77957881420
-
Persistence with statins and onset of rheumatoid arthritis: A population-based cohort study
-
Chodick G, Amital H, Shalem Y, et al. Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 2010; 7(9): e1000336.
-
(2010)
PLoS Med
, vol.7
, Issue.9
-
-
Chodick, G.1
Amital, H.2
Shalem, Y.3
-
145
-
-
34248669556
-
Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort
-
Okamoto H, Koizumi K, Kamitsuji S, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007; 34(5): 964-968.
-
(2007)
J Rheumatol
, vol.34
, Issue.5
, pp. 964-968
-
-
Okamoto, H.1
Koizumi, K.2
Kamitsuji, S.3
-
146
-
-
2942670131
-
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomized placebo-controlled trial
-
McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004; 363(9426): 2015-2021.
-
(2004)
Lancet
, vol.363
, Issue.9426
, pp. 2015-2021
-
-
McCarey, D.W.1
McInnes, I.B.2
Madhok, R.3
-
147
-
-
66049160738
-
Should patients with rheumatoid arthritis receive statin therapy?
-
Ridker PM, Solomon DH. Should patients with rheumatoid arthritis receive statin therapy? Arthritis Rheum 2009; 60(5): 1205-1209.
-
(2009)
Arthritis Rheum
, vol.60
, Issue.5
, pp. 1205-1209
-
-
Ridker, P.M.1
Solomon, D.H.2
-
148
-
-
77950325065
-
Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: Evidence for substantial undertreatment of lipid-associated cardiovascular risk?
-
Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 2010; 69(4): 683-688.
-
(2010)
Ann Rheum Dis
, vol.69
, Issue.4
, pp. 683-688
-
-
Toms, T.E.1
Panoulas, V.F.2
Douglas, K.M.3
-
149
-
-
78751693922
-
Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: An explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial
-
Semb AG, Holme I, Kvien TK, Pedersen TR. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford) 2011; 50(2): 324-329.
-
(2011)
Rheumatology (Oxford)
, vol.50
, Issue.2
, pp. 324-329
-
-
Semb, A.G.1
Holme, I.2
Kvien, T.K.3
Pedersen, T.R.4
-
150
-
-
19944433437
-
Simvastatin improves endothelial function in patients with rheumatoid arthritis
-
Hermann F, Forster A, Chenevard R, et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005; 45(3): 461-464.
-
(2005)
J Am Coll Cardiol
, vol.45
, Issue.3
, pp. 461-464
-
-
Hermann, F.1
Forster, A.2
Chenevard, R.3
-
151
-
-
77956637898
-
A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis
-
Goto M. A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol 2010; 20(3): 238-243.
-
(2010)
Mod Rheumatol
, vol.20
, Issue.3
, pp. 238-243
-
-
Goto, M.1
-
152
-
-
34547839642
-
A pravastatin dose-escalation study in systemic lupus erythematosus
-
Costenbader KH, Liang MH, Chibnik LB, et al. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 2007; 27(11): 1071-1077.
-
(2007)
Rheumatol Int
, vol.27
, Issue.11
, pp. 1071-1077
-
-
Costenbader, K.H.1
Liang, M.H.2
Chibnik, L.B.3
|